Q28838
PR
Gene name |
ADRA2A |
Protein name |
Alpha-2A adrenergic receptor |
Names |
Alpha-2A adrenoreceptor, Alpha-2A adrenoceptor, Alpha-2AAR, Alpha-2D adrenergic receptor |
Species |
Bos taurus (Bovine) |
KEGG Pathway |
bta:282135 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
2 structures for Q28838
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| 6K41 | EM | 290 A | R | 37-44 | PDB |
| AF-Q28838-F1 | Predicted | AlphaFoldDB |
143 variants for Q28838
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs433656680 | 8 | L>R | No | EVA | |
| rs452057134 | 12 | S>R | No | EVA | |
| rs464114214 | 13 | F>C | No | EVA | |
| rs437515631 | 14 | A>S | No | EVA | |
| rs456015391 | 16 | M>L | No | EVA | |
| rs475303352 | 18 | S>Y | No | EVA | |
| rs442333497 | 23 | A>S | No | EVA | |
| rs876281653 | 25 | N>T | No | EVA | |
| rs876011548 | 31 | T>A | No | EVA | |
| rs876077892 | 37 | G>A | No | EVA | |
| rs439851696 | 41 | T>P | No | EVA | |
| rs458182029 | 44 | S>P | No | EVA | |
| rs483131774 | 47 | V>G | No | EVA | |
| rs443640708 | 51 | L>R | No | EVA | |
| rs521122340 | 70 | I>V | No | EVA | |
| rs462203346 | 75 | T>P | No | EVA | |
| rs481355613 | 76 | S>I | No | EVA | |
| rs466845448 | 81 | A>E | No | EVA | |
| rs448404117 | 81 | A>P | No | EVA | |
| rs445810900 | 82 | P>A | No | EVA | |
| rs464081452 | 82 | P>L | No | EVA | |
| rs437703388 | 84 | N>H | No | EVA | |
| rs455952495 | 86 | F>C | No | EVA | |
| rs468227336 | 91 | A>S | No | EVA | |
| rs454380968 | 106 | L>P | No | EVA | |
| rs433313904 | 147 | Y>C | No | EVA | |
| rs451966223 | 152 | Q>K | No | EVA | |
| rs476701872 | 156 | Y>H | No | EVA | |
| rs443774121 | 171 | T>P | No | EVA | |
| rs462105862 | 172 | V>G | No | EVA | |
| rs474193146 | 174 | V>G | No | EVA | |
| rs441213412 | 175 | I>L | No | EVA | |
| rs460407048 | 177 | A>G | No | EVA | |
| rs445803018 | 181 | F>L | No | EVA | |
| rs457805524 | 181 | F>S | No | EVA | |
| rs482508732 | 185 | I>V | No | EVA | |
| rs449655941 | 187 | F>C | No | EVA | |
| rs468266380 | 188 | E>A | No | EVA | |
| rs447205576 | 191 | R>S | No | EVA | |
| rs466477584 | 193 | R>G | No | EVA | |
| rs433510392 | 194 | S>G | No | EVA | |
| rs451902853 | 194 | S>R | No | EVA | |
| rs476836301 | 196 | Q>H | No | EVA | |
| rs437408978 | 198 | S>A | No | EVA | |
| rs455792073 | 199 | A>V | No | EVA | |
| rs441157213 | 203 | C>R | No | EVA | |
| rs459734552 | 203 | C>W | No | EVA | |
| rs472281301 | 205 | I>M | No | EVA | |
| rs439497638 | 211 | Y>N | No | EVA | |
| rs457895112 | 211 | Y>S | No | EVA | |
| rs482595220 | 215 | S>P | No | EVA | |
| rs449803694 | 222 | A>G | No | EVA | |
| rs461813186 | 225 | L>P | No | EVA | |
| rs480411567 | 226 | I>M | No | EVA | |
| rs447236791 | 234 | I>M | No | EVA | |
| rs465796233 | 239 | K>Q | No | EVA | |
| rs433444631 | 239 | K>R | No | EVA | |
| rs445528535 | 241 | R>L | No | EVA | |
| rs470500887 | 242 | T>P | No | EVA | |
| rs437347313 | 243 | R>L | No | EVA | |
| rs137632851 | 247 | S>G | No | EVA | |
| rs453264855 | 250 | G>C | No | EVA | |
| rs471573270 | 250 | G>V | No | EVA | |
| rs438781102 | 252 | D>V | No | EVA | |
| rs136394479 | 253 | A>P | No | EVA | |
| rs133932581 | 254 | T>P | No | EVA | |
| rs476321056 | 260 | G>R | No | EVA | |
| rs722642425 | 332 | P>L | No | EVA | |
| rs480329032 | 366 | P>Q | No | EVA | |
| rs459459858 | 367 | A>G | No | EVA | |
| rs477769491 | 368 | E>G | No | EVA | |
| rs444852839 | 369 | E>G | No | EVA | |
| rs482627496 | 370 | R>G | No | EVA | |
| rs449444358 | 370 | R>P | No | EVA | |
| rs434991610 | 371 | S>F | No | EVA | |
| rs465299199 | 372 | G>C | No | EVA | |
| rs476310448 | 375 | A>D | No | EVA | |
| rs443528787 | 376 | K>Q | No | EVA | |
| rs455507968 | 377 | A>E | No | EVA | |
| rs473977814 | 378 | S>A | No | EVA | |
| rs441015947 | 379 | R>G | No | EVA | |
| rs459394513 | 379 | R>H | No | EVA | |
| rs459394513 | 379 | R>P | No | EVA | |
| rs438409579 | 380 | W>G | No | EVA | |
| rs463376302 | 381 | R>C | No | EVA | |
| rs449465541 | 382 | G>R | No | EVA | |
| rs468114793 | 383 | R>G | No | EVA | |
| rs480020825 | 383 | R>Q | No | EVA | |
| rs447008783 | 384 | Q>* | No | EVA | |
| rs447008783 | 384 | Q>E | No | EVA | |
| rs447008783 | 384 | Q>K | No | EVA | |
| rs465287040 | 384 | Q>P | No | EVA | |
| rs432496403 | 385 | N>D | No | EVA | |
| rs450779293 | 385 | N>K | No | EVA | |
| rs469394016 | 387 | E>A | No | EVA | |
| rs474130287 | 391 | T>N | No | EVA | |
| rs455525398 | 391 | T>P | No | EVA | |
| rs434538106 | 395 | A>G | No | EVA | |
| rs135341291 | 396 | V>G | No | EVA | |
| rs453169947 | 396 | V>L | No | EVA | |
| rs438552621 | 397 | V>G | No | EVA | |
| rs109805489 | 398 | I>M | No | EVA | |
| rs463464060 | 398 | I>V | No | EVA | |
| rs461566640 | 400 | V>A | No | EVA | |
| rs461566640 | 400 | V>E | No | EVA | |
| rs461566640 | 400 | V>G | No | EVA | |
| rs446996701 | 401 | F>L | No | EVA | |
| rs480185967 | 401 | F>V | No | EVA | |
| rs459006859 | 402 | V>G | No | EVA | |
| rs477294495 | 403 | V>A | No | EVA | |
| rs477294495 | 403 | V>G | No | EVA | |
| rs450866820 | 404 | C>S | No | EVA | |
| rs469527462 | 408 | F>L | No | EVA | |
| rs136541178 | 411 | T>P | No | EVA | |
| rs136901800 | 412 | Y>S | No | EVA | |
| rs135080607 | 413 | T>P | No | EVA | |
| rs436341817 | 415 | T>R | No | EVA | |
| rs434718991 | 421 | V>G | No | EVA | |
| rs467634756 | 421 | V>L | No | EVA | |
| rs453110964 | 422 | P>R | No | EVA | |
| rs471556450 | 423 | P>A | No | EVA | |
| rs432167911 | 424 | T>P | No | EVA | |
| rs475552248 | 426 | F>S | No | EVA | |
| rs442380603 | 427 | K>T | No | EVA | |
| rs460996294 | 428 | F>V | No | EVA | |
| rs473674920 | 428 | F>Y | No | EVA | |
| rs207856101 | 432 | F>I | No | EVA | |
| rs440702545 | 440 | N>T | No | EVA | |
| rs459100037 | 442 | V>I | No | EVA | |
| rs477382834 | 445 | T>A | No | EVA | |
| rs477382834 | 445 | T>P | No | EVA | |
| rs444604218 | 446 | I>T | No | EVA | |
| rs462970588 | 447 | F>S | No | EVA | |
| rs481606218 | 449 | H>P | No | EVA | |
| rs467018839 | 450 | D>A | No | EVA | |
| rs448383831 | 450 | D>H | No | EVA | |
| rs479021450 | 451 | F>L | No | EVA | |
| rs446734418 | 451 | F>S | No | EVA | |
| rs465267026 | 457 | K>Q | No | EVA | |
| rs457169306 | 458 | I>L | No | EVA | |
| rs469046281 | 462 | G>E | No | EVA | |
| rs436117399 | 465 | K>M | No | EVA | |
| rs472775169 | 469 | V>G | No | EVA |
No associated diseases with Q28838
1 regional properties for Q28838
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | GPCR, rhodopsin-like, 7TM | 65 - 444 | IPR017452 |
4 GO annotations of cellular component
| Name | Definition |
|---|---|
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| dopaminergic synapse | A synapse that uses dopamine as a neurotransmitter. |
| integral component of plasma membrane | The component of the plasma membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane. |
| receptor complex | Any protein complex that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function. |
10 GO annotations of molecular function
| Name | Definition |
|---|---|
| alpha-2C adrenergic receptor binding | Binding to an alpha-2C adrenergic receptor. |
| alpha2-adrenergic receptor activity | Combining with epinephrine or norepinephrine to initiate a change in cell activity via activation of a G protein, with pharmacological characteristics of alpha2-adrenergic receptors; the activity involves transmitting the signal to the Gi alpha subunit of a heterotrimeric G protein. |
| epinephrine binding | Binding to epinephrine, a hormone produced by the medulla of the adrenal glands that increases heart activity, improves the power and prolongs the action of muscles, and increases the rate and depth of breathing. It is synthesized by the methylation of norepinephrine. |
| G protein-coupled receptor activity | Combining with an extracellular signal and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex. |
| heterotrimeric G-protein binding | Binding to a heterotrimeric G-protein. |
| norepinephrine binding | Binding to norepinephrine, (3,4-dihydroxyphenyl-2-aminoethanol), a hormone secreted by the adrenal medulla and a neurotransmitter in the sympathetic peripheral nervous system and in some tracts of the CNS. It is also the biosynthetic precursor of epinephrine. |
| protein heterodimerization activity | Binding to a nonidentical protein to form a heterodimer. |
| protein homodimerization activity | Binding to an identical protein to form a homodimer. |
| protein kinase binding | Binding to a protein kinase, any enzyme that catalyzes the transfer of a phosphate group, usually from ATP, to a protein substrate. |
| thioesterase binding | Binding to a thioesterase. |
20 GO annotations of biological process
| Name | Definition |
|---|---|
| activation of protein kinase B activity | Any process that initiates the activity of the inactive enzyme protein kinase B. |
| adenylate cyclase-activating adrenergic receptor signaling pathway | An adenylate cyclase-activating G protein-coupled receptor signaling pathway initiated by a ligand binding to an adrenergic receptor on the surface of the target cell, and ending with the regulation of a downstream cellular process. |
| adenylate cyclase-inhibiting adrenergic receptor signaling pathway | An adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway initiated by a ligand binding to an adrenergic receptor, and ending with the regulation of a downstream cellular process. |
| cellular response to hormone stimulus | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hormone stimulus. |
| fear response | The response of an organism to a perceived external threat. |
| glucose homeostasis | Any process involved in the maintenance of an internal steady state of glucose within an organism or cell. |
| negative regulation of insulin secretion involved in cellular response to glucose stimulus | Any process that decreases the frequency, rate or extent of the regulated release of insulin that contributes to the response of a cell to glucose. |
| negative regulation of lipid catabolic process | Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of lipids. |
| phospholipase C-activating adrenergic receptor signaling pathway | A phospholipase C-activating receptor G protein-coupled receptor signaling pathway initiated by ligand binding to an adrenergic receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. |
| platelet activation | A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug. |
| positive regulation of cell migration | Any process that activates or increases the frequency, rate or extent of cell migration. |
| positive regulation of cytokine production | Any process that activates or increases the frequency, rate or extent of production of a cytokine. |
| positive regulation of epidermal growth factor-activated receptor activity | Any process that activates or increases the frequency, rate or extent of EGF-activated receptor activity. |
| positive regulation of MAP kinase activity | Any process that activates or increases the frequency, rate or extent of MAP kinase activity. |
| positive regulation of membrane protein ectodomain proteolysis | Any process that activates or increases the frequency, rate or extent of membrane protein ectodomain peptidolysis. |
| positive regulation of wound healing | Any process that increases the rate, frequency, or extent of the series of events that restore integrity to a damaged tissue, following an injury. |
| receptor transactivation | The process in which a receptor is activated by another receptor. Receptor transactivation can occur through different mechanisms and includes cross-talk between signaling pathways where one receptor activates a receptor for a different ligand, and also activation of subunits within a receptor oligomer. |
| regulation of smooth muscle contraction | Any process that modulates the frequency, rate or extent of smooth muscle contraction. |
| regulation of synaptic vesicle exocytosis | Any process that modulates the frequency, rate or extent of synaptic vesicle exocytosis. |
| regulation of vasoconstriction | Any process that modulates the frequency, rate or extent of reductions in the diameter of blood vessels. |
4 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| P18130 | ADRA1A | Alpha-1A adrenergic receptor | Bos taurus (Bovine) | PR |
| P46626 | ADRB3 | Beta-3 adrenergic receptor | Bos taurus (Bovine) | PR |
| P41984 | CHRM3 | Muscarinic acetylcholine receptor M3 | Bos taurus (Bovine) | PR |
| P08913 | ADRA2A | Alpha-2A adrenergic receptor | Homo sapiens (Human) | PR |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MFRQEQPLAE | GSFAPMGSLQ | PDAGNASWNG | TEAPGGGARA | TPYSLQVTLT | LVCLAGLLML |
| 70 | 80 | 90 | 100 | 110 | 120 |
| FTVFGNVLVI | IAVFTSRALK | APQNLFLVSL | ASADILVATL | VIPFSLANEV | MGYWYFGKAW |
| 130 | 140 | 150 | 160 | 170 | 180 |
| CEIYLALDVL | FCTSSIVHLC | AISLDRYWSI | TQAIEYNLKR | TPRRIKAIIV | TVWVISAVIS |
| 190 | 200 | 210 | 220 | 230 | 240 |
| FPPLISFEKK | RGRSGQPSAE | PRCEINDQKW | YVISSSIGSF | FAPCLIMILV | YVRIYQIAKR |
| 250 | 260 | 270 | 280 | 290 | 300 |
| RTRVPPSRRG | PDATAAELPG | SAERRPNGLG | PERGGVGPVG | AEVESLQVQL | NGAPGEPAPA |
| 310 | 320 | 330 | 340 | 350 | 360 |
| GPPDADALDL | EESSSSEHAE | RPPGSRRSER | GPRAKGKARA | SQVKPGDSLP | RRGPGATGLG |
| 370 | 380 | 390 | 400 | 410 | 420 |
| APTAGPAEER | SGGGAKASRW | RGRQNREKRF | TFVLAVVIGV | FVVCWFPFFF | TYTLTAIGCP |
| 430 | 440 | 450 | 460 | ||
| VPPTLFKFFF | WFGYCNSSLN | PVIYTIFNHD | FRRAFKKILC | RGDRKRIV |